Ivermectin B1a aglycone is an acid degradation product produced by hydrolysis of the disaccharide unit of ivermectin. It can inhibit nematode larval development, but does not cause paralytic activity.
Ivermectin B1a monosaccharide is produced by selective hydrolysis of the terminal saccharide unit of ivermectin. It can inhibit nematode larval development, but does not cause paralytic activity. This compound has been used as a probe to detect some types of ivermectin resistance.
Ivermectin B1b is the minor component . It produces antiparasitic activity by binding to glutamate-gated chloride channels expressed on nematode neurons and pharyngeal muscle cells, inducing irreversible channel opening and very long-lasting hyperpolarization depolarization of the neuron muscle cell, thereby blocking further function.
2,3-Dehydro-3,4-dihydro ivermectin is an analog of ivermectin and an anthelmintic. 2,3-Dehydro-3,4-dihydro ivermectin has activity against L. amazonensis promastigotes and amastigotes ( IC 50 s=13.8 and 3.6 μM, respectively) without inducing cytotoxicity to macrophages ( IC 50 = 65.5 μM).